DE60017733T2 - Verwendung von riluzol zur behandlung multipler sklerose - Google Patents

Verwendung von riluzol zur behandlung multipler sklerose Download PDF

Info

Publication number
DE60017733T2
DE60017733T2 DE60017733T DE60017733T DE60017733T2 DE 60017733 T2 DE60017733 T2 DE 60017733T2 DE 60017733 T DE60017733 T DE 60017733T DE 60017733 T DE60017733 T DE 60017733T DE 60017733 T2 DE60017733 T2 DE 60017733T2
Authority
DE
Germany
Prior art keywords
treatment
use according
multiple sclerosis
riluzole
interferon beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60017733T
Other languages
German (de)
English (en)
Other versions
DE60017733D1 (de
Inventor
Chris Polman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vrije Universiteit Amsterdam
Original Assignee
Vrije Universiteit Amsterdam
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vrije Universiteit Amsterdam filed Critical Vrije Universiteit Amsterdam
Publication of DE60017733D1 publication Critical patent/DE60017733D1/de
Application granted granted Critical
Publication of DE60017733T2 publication Critical patent/DE60017733T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60017733T 1999-06-04 2000-06-02 Verwendung von riluzol zur behandlung multipler sklerose Expired - Lifetime DE60017733T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP99201788 1999-06-04
EP99201788 1999-06-04
US17432800P 2000-01-04 2000-01-04
US174328P 2000-01-04
PCT/IB2000/000933 WO2000074676A1 (en) 1999-06-04 2000-06-02 Use of riluzole for the treatment of multiple sclerosis

Publications (2)

Publication Number Publication Date
DE60017733D1 DE60017733D1 (de) 2005-03-03
DE60017733T2 true DE60017733T2 (de) 2006-01-12

Family

ID=56290027

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60017733T Expired - Lifetime DE60017733T2 (de) 1999-06-04 2000-06-02 Verwendung von riluzol zur behandlung multipler sklerose

Country Status (11)

Country Link
EP (2) EP1552831B1 (enExample)
JP (1) JP2003522121A (enExample)
AT (2) ATE287713T1 (enExample)
AU (1) AU777537B2 (enExample)
CA (1) CA2375874A1 (enExample)
DE (1) DE60017733T2 (enExample)
ES (1) ES2235896T3 (enExample)
NZ (1) NZ515685A (enExample)
PT (1) PT1187612E (enExample)
SI (1) SI1187612T1 (enExample)
WO (1) WO2000074676A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1100504A2 (en) 1998-07-02 2001-05-23 Eisai Co., Ltd. Pharmaceutical compositions and their uses for treatment of demyelinating disorders
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
IL136687A0 (en) * 2000-06-12 2001-06-14 Mor Research Applic Ltd Pharmaceutical composition for the treatment of multiple sclerosis
EP1778286A4 (en) * 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
ITMI20061274A1 (it) * 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Vettori nanoparticellari lipidici contenenti riluzolo e composizioni farmaceutiche che li contengono
EP2228054A1 (en) 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
WO2010113225A1 (en) * 2009-03-30 2010-10-07 Yutoku Pharmaceutical Industries Co., Ltd. Riluzole-containing transdermal patch
EA201791110A1 (ru) * 2014-11-21 2017-11-30 Биохэвен Фармасьютикэл Холдинг Компани Лтд. Сублингвальное введение рилузола
BR112017010700A2 (pt) * 2014-11-26 2018-05-08 Medicinova Inc combinação de ibudilaste e riluzol e métodos de uso da mesma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
AU7298196A (en) * 1995-10-25 1997-05-15 Janssen Pharmaceutica N.V. Infusions of neuroprotectants and perfluorochemicals
CN1202109A (zh) * 1995-11-15 1998-12-16 山之内制药株式会社 红藻氨酸神经细胞毒性抑制剂及吡啶并噻嗪衍生物
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
JP4120713B2 (ja) * 1997-09-04 2008-07-16 大塚製薬株式会社 多発性硬化症治療剤
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose

Also Published As

Publication number Publication date
EP1552831A1 (en) 2005-07-13
ES2235896T3 (es) 2005-07-16
WO2000074676A1 (en) 2000-12-14
EP1187612A1 (en) 2002-03-20
ATE419851T1 (de) 2009-01-15
EP1552831B1 (en) 2009-01-07
ATE287713T1 (de) 2005-02-15
AU777537B2 (en) 2004-10-21
EP1187612B1 (en) 2005-01-26
AU5421900A (en) 2000-12-28
NZ515685A (en) 2002-12-20
PT1187612E (pt) 2005-05-31
CA2375874A1 (en) 2000-12-14
SI1187612T1 (en) 2005-06-30
JP2003522121A (ja) 2003-07-22
DE60017733D1 (de) 2005-03-03

Similar Documents

Publication Publication Date Title
DE69636308T2 (de) Tumornekrosefaktor alpha (tnf-alpha) hemmende arzneistoffe
DE69805202T2 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
DE69100282T3 (de) Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
DE602004005617T2 (de) Mittel zur behandlung von glaukomatöser retinopathie und optischer neuropathie
EP0506658B1 (en) Compositions and method for treating painful, inflammatory or allergic disorders
EP0185210B1 (de) Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten
DE60017733T2 (de) Verwendung von riluzol zur behandlung multipler sklerose
EP1217998A2 (de) Verwendung von (+)-tramadol, o-demethyltramadol bzw. (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol bzw. (+)-o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
DE69232516T2 (de) Behandlung von neurologischen Zuständen durch eine Interleukin-i-inhibierende Verbindung
DE3317692A1 (de) Verwendung von metkephamid oder eines pharmazeutisch unbedenklichen salzes hiervon als analgetikum bei traechtigen weiblichen tieren und insbesondere bei schwangeren frauen
DE69834638T2 (de) Zusammensetzung zur Behandlung von Augenhypertension oder Glaukom
EP0166183B1 (de) Verwendung von Hydroxyindolderivaten zur Herstellung eines Arzneimittels zur Senkung des Blutdrucks
DE2206570C3 (de) Verwendung von (+)-Catechin
DE69125204T2 (de) Therapeutische Anwendung von Histamin-H3-Agonisten, neue Wirkstoffe und Verwendung zur Herstellung von Arzneimitteln
DE69308762T2 (de) Behandlung des Muskulschwunds
HUT71497A (en) New pharmaceutical use of 1,2,3,4,4a,5,10,10a-octahydro-benzo(g) quinoline derivatives
EP0028660B1 (de) Xanthinoxydasehemmer und Verwendung von Benztriazinderivaten
DE60034110T2 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
DE3723248A1 (de) Verwendung von thiosulfinsaeurederivaten zur behandlung von entzuendungserkrankungen
DE2633891C2 (de) Tris-(hydroxymethyl)-aminomethansalz der 2-(5-Benzoylthienyl)-α-methylessigsäure, Verfahren zu dessen Herstellung und dieses enthaltende pharmazeutische Zusammensetzungen
EP0845264A1 (de) Teil- oder Vollextrakt aus nicht fermentierter Camellia sinensis L.
DE60012183T2 (de) Verwendung einer makrolid-verbindung zur herstellung eines medikaments zur behandlung von gehirnschäden aufgrund von ischämie oder blutungen
EP1528922B1 (de) Verwendung von treosulfan und derivaten davon zur behandlung der multiplen sklerose
DE69919191T2 (de) Heilmittel für die stenose des rückenmarkkanals
EP0771202A1 (de) VERWENDUNG VON (S)-ADENOSYL-L-METHIONIN (SAMe) UND DESSEN PHYSIOLOGISCH VERTRÄGLICHEN SALZEN ZUR BEHANDLUNG VON REPERFUSIONSSCHÄDEN, DIE DURCH TEMPORÄRE FOKALE ISCHÄMIE AUSGELÖST WERDEN

Legal Events

Date Code Title Description
8364 No opposition during term of opposition